Importance of receptor-targeted systems in the battle against atherosclerosis

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5897-5903

  Rosas, Elisabet ^a,b   Sobenin, Igor ^c   Orekhov, Alexander ^c   Edelman, Elazer R ^a,d   Balcells, Mercedes ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^c Institute for Atherosclerosis Research   (Russian Federation)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Biomarkers; Direct targeting; Early diagnosis; Endothelial cells; Receptors

Indexed keywords

BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUMAGILLIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; N(G),N(G) DIMETHYLARGININE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FLUORESCENCE; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CYTOKINES; EARLY DIAGNOSIS; ENDOTHELIUM, VASCULAR; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84884271909     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319330010     Document Type: Review

References (49)

1. Aalto K, Maksimow M, Juonala M, et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arteriosclerosis, Thrombosis, Vascular Biol 2012; 32(2): 523-32.
2. Ibrahim Dezayee Z. Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus. Int J Applied Basic Med Res 2011; 1(2): 109.
3. Chen L, Yang Z, Lu B, et al. Serum CXC ligand 5 is a new marker of subclinical atherosclerosis in type 2 diabetes. Clinical Endocrinol 2011; 75(6): 766-70.
4. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chem 2008; 54(1): 24-38.
5. Noji Y, Kajinami K, Kawashiri M, et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis. Clinical Chem Laboratory Med 2005; 39(5): 380-4.
6. Jönsson S, Lundberg A, Kälvegren H, Bergström I, Szymanowski A, Jonasson L. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PloS one 2011; 6(4): e19340.
7. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clinical Chem 2009; 55(2): 229-38.
8. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113(1): 38-43.
9. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115(4): 459-67.
10. Tsai MH, Chang CL, Yu YS, et al. Chemical Analysis of CReactive Protein Synthesized by Human Aortic Endothelial Cells Under Oxidative Stress. Analytical Chem 2012; 84(21): 9646-54.
11. Bisoendial RJ, Kastelein JJP, Peters SLM, et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 2007; 48(4): 952-60.
12. Davì G, Patrono C. Platelet activation and atherothrombosis. New Eng J Med 2007; 357(24): 2482-94.
13. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cellderived microparticles in haemostasis and vascular medicine. Thrombosis Haemostasis 2009; 439-51.
14. Smadja DM, d' Audigier C, Bièche I, et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arteriosclerosis, Thrombosis, Vascular Biol 2011; 31(3): 551-9.
15. Burger D, Touyz R. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertension 2012; 6(2): 85-99.
16. Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clinical Chem 2011; 57(12): 1757-61.
17. Lanuti P, Santilli F, Marchisio M, et al. A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: Relevance for the evaluation of endothelial dysfunction. J Immunological Methods 2012; 380(1-2): 16-22.
18. Cheng S, Wang N, Larson MG, et al. Circulating angiogenic cell populations, vascular function, and arterial stiffness. Atherosclerosis Elsevier Ireland Ltd; 2012; 220(1): 145-50.
19. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction: Its Role in Hypercholesterolemia. Circulation 1998; 98(18): 1842-7.
20. Di Franco M, Spinelli FR, Metere A, et al. Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflammation 2012; 2012: 347268.
21. Ayer JG, Harmer J A, Nakhla S, et al. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arteriosclerosis, Thrombosis, Vascular Biol 2009; 29(6): 943-9.
22. von zur Muhlen C, Schiffer E, Sackmann C, et al. Urine proteome analysis reflects atherosclerotic disease in an ApoE-/-mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Molecular & cellular proteomics: MCP 2012; 11(7): M111.013847.
23. Würtz P, Raiko JR, Magnussen CG, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J. 2012; 33(18): 2307-16.
24. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113(18): 2245-52.
25. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v) beta3-integrin-targeted nanoparticles. Circulation 2003; 108(18): 2270-4.
26. Brien KDO, Allen MD, Mcdonald T, et al. Vascular Cell Adhesion Molecule-1 Is Expressed in Human Coronary Atherosclerotic Plaques Implications for the Mode of Progression of Advanced Coronary Atherosclerosis Adsorption assay Riboprobe Preparation 1993; 92: 945-51.
27. Boyle J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vascular Pharmacol 2005; 3: 63-8.
28. Kitagawa T, Kosuge H, Uchida M, et al. RGD-conjugated human ferritin nanoparticles for imaging vascular inflammation and angiogenesis in experimental carotid and aortic disease. Molecular imaging and biology: MIB: the official Publication Academy Mol Imaging 2012; 14(3): 315-24.
29. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arteriosclerosis, Thrombosis, Vascular Biol 2006; 26(9): 2103-9.
30. Zagorchev L, Mulligan-Kehoe MJ. Advances in imaging angiogenesis and inflammation in atherosclerosis. Thrombosis Haemostasis 2011; 105(5): 820-7.
31. Morishige K, Kacher DF, Libby P, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010; 122(17): 1707-15.
32. Woodward P, Liu Y, Pressly E, Abendschein D, Hawker CJ, Welch MJ. PATENT. pdf. 2011.
33. Burtea C, Laurent S, Murariu O, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovascular Res 2008; 78(1): 148-57.
34. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. αvβ3 Integrin Expression in Normal and Atherosclerotic Artery. Circulation Res 1995; (77): 1129-35.
35. Lam MK, Al-Ansari S, van Dam GM, et al. Single-Chain VEGF/Cy5.5 Targeting VEGF Receptors to Indicate Atherosclerotic Plaque Instability. Molecular imaging and biology: MIB: the official publication Academy Mol Imaging 2012; Sep 28.
36. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB journal: official publication of the Federation Am Soc Experimental Biol 1999; 13(1): 9-22.
37. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arteriosclerosis, Thrombosis, Vascular Biol 2005; 25(10): 2054-61.
38. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxidants Redox Signaling 2009; 11(9): 2333-9.
39. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovascular Res 2006; 69(3): 625-35.
40. Hu JH, Du L, Chu T, Otsuka G. NIH Public Access 2010; 121(14): 206-21.
41. Deguchi J, Aikawa M, Tung CH, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006; 114(1): 55-62.
42. Ripplinger CM, Kessinger CW, Li C, et al. Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging. Arteriosclerosis, Thrombosis, Vascular Biol 2012; 32(11): 2616-24.
43. Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci USA 2004; 101(34): 12634-9.
44. Saxena A, Kessinger CW, Thompson B, et al. High-Resolution Optical Mapping of Inflammatory Macrophages Following Endovascular Arterial Injury. Molecular imaging and biology: MIB: the official Publication Academy Mol Imaging 2012;
45. Maile L A, Busby WH, Nichols TC, et al. A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. Sci Translational Med 2010; 2(18): 18ra11.
46. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348.
47. Herbst RS. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer. J Clinical Oncol 2002; 20(22): 4440-7.
48. Tran TD, Caruthers SD, Hughes M, et al. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomed 2007; 2(4): 515-26.
49. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473(7347): 317-25.